Skip to main content
Premium Trial:

Request an Annual Quote

Bio-Rad Awarded $24M in 10x Genomics Patent Infringement Lawsuit

NEW YORK (GenomeWeb) – A jury has awarded Bio-Rad Laboratories $23.9 million in damages in the firm's patent infringement suit against 10x Genomics, the company announced yesterday.

The Federal District Court jury found that three US patents owned by the University of Chicago and exclusively licensed to Bio-Rad were willfully infringed by 10x. Specifically, the jury unanimously found that all single-cell and linked-read genomics products sold by 10x willfully infringed the patents, according to a statement from Bio-Rad.

In a separate action before the International Trade Commission, an administrative law judge made an initial determination that certain microfluidic devices used by 10x in its products infringe patent rights owned by Bio-Rad, the firm said.

Bio-Rad filed a lawsuit in 2017, claiming infringement on a separate set of seven US patents.

In a statement to GenomeWeb, a 10x spokesperson said, "We strongly disagree with the verdict. We will immediately file an appeal."

The Scan

J&J Booster Support

A US Food and Drug Administration advisory panel has voted to support a booster dose of Johnson & Johnson's SARS-CoV-2 vaccine, according to the Los Angeles Times.

To Keep the Cases Moving

The president of the UK Royal College of Pathologists tells the Financial Times that more investment is needed to tackle a backlog of cases.

NAS Expels Archaeologist

Science reports Luis Jaime Castillo Butters' expulsion is the first of an international member from the US National Academy of Sciences.

PLOS Papers on Angelman Syndrome-Like Cases, Salmonella Paratyphi A, SARS-CoV-2 in Brazil

In PLOS this week: exome sequencing analysis of Angelman syndrome-like cases, genetic epidemiology of Salmonella Paratyphi A, and more.